Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2′OMethyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 14; no. 11; p. 1113
• Main Authors: Georgiadou, Michaella, Christou, Melina, Sokratous, Kleitos, Wengel, Jesper, Michailidou, Kyriaki, Kyriacou, Kyriacos, Koutsoulidou, Andrie, Mastroyiannopoulos, Nikolaos P., Phylactou, Leonidas A.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 30.10.2021; MDPI
• Subjects: antisense oligonucleotides; Brand names; Clinical trials; Design optimization; DMD; Drug dosages; exon skipping; FDA approval; LNA/2′OMe; mdx; Muscular dystrophy; Mutation; Patients; Proteins; United States > US
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph14111113

Duchenne muscular dystrophy (DMD) is a fatal disorder characterised by progressive muscle wasting. It is caused by mutations in the dystrophin gene, which disrupt the open reading frame leading to the loss of functional dystrophin protein in muscle fibres. Antisense oligonucleotide (AON)-mediated skipping of the mutated exon, which allows production of a truncated but partially functional dystrophin protein, has been at the forefront of DMD therapeutic research for over two decades. Nonetheless, novel nucleic acid modifications and AON designs are continuously being developed to improve the clinical benefit profile of current drugs in the DMD pipeline. We herein designed a series of 15mer and 20mer AONs, consisting of 2′O-Methyl (2′OMe)- and locked nucleic acid (LNA)-modified nucleotides in different percentage compositions, and assessed their efficiency in inducing exon 23 skipping and dystrophin restoration in locally injected muscles of mdx mice. We demonstrate that LNA/2′OMe AONs with a 30% LNA composition were significantly more potent in inducing exon skipping and dystrophin restoration in treated mdx muscles, compared to a previously tested 2′OMe AON and LNA/2′OMe chimeras with lower or higher LNA compositions. These results underscore the therapeutic potential of LNA/2′OMe AONs, paving the way for further experimentation to evaluate their benefit-toxicity profile following systemic delivery.